Oct 18 (Reuters) - Getinge :Q3 order intake increased by 2.2% to sek 7,334 m (7,176). Order intake increased organically by 4.7%..Getinge q3 - net sales fell by 3.4% to sek 6,696 m (6,929). Net sales decreased organically by 0.7%..Q3 ebita 1* declined by 31.6% to sek 659 m.Getinge says organic sales growth is expected to be slightly positive in 2017..Getinge says currency transaction effects are expected to have a positive impact of approximately sek 250 m on getinge’s 2017 ebit.Reuters poll: getinge q3 order intake was seen at 7.2 billion sek, adjusted. Ebita at 904 million.Says net sales were adversely impacted by lower order intake in q2 and higher expenses partly related to work on preparing proposed distribution of patient & post-acute care business area.Getinge says remainder of 2017 will be challenging, partly because the fourth quarter is our most important quarter in terms of sales and profitability, and partly because we have large-scale projects to complete before the start of 2018.Getinge says aim is to distribute and list ppac division before end of year, on condition of a decision by the board and the approval of an extraordinary general meeting.
Sept 12 (Reuters) - Cooper Companies Inc :The Cooper Companies announces definitive agreement to acquire Paragard® IUD from Teva.Cooper Companies Inc - boards of directors of both Cooper and Teva have unanimously approved transaction.Cooper Companies Inc - excluding items, deal to be accretive to Cooper's gross and operating margins and about $0.70 to $0.75 accretive to EPS in year one.Cooper Companies Inc - acquired business includes Teva's manufacturing facility in Buffalo, NY, which exclusively produces Paragard IUD.
Aug 14 (Reuters) - WILLIAM DEMANT HOLDING A/S :INCREASES GUIDANCE FOR 2017.GROUP ORGANIC GROWTH OF 8%.EXPECTS AN EBIT OF DKK 2.3-2.6 BILLION (PREVIOUSLY DKK 2.2-2.5 BILLION) BEFORE RESTRUCTURING COSTS OF AROUND DKK 175 MILLION (PREVIOUSLY AROUND DKK 200 MILLION) IN 2017.H1 REVENUE DKK 6.51 BILLION (REUTERS POLL DKK 6.38 BILLION).H1 EBIT ADJUSTED. DKK 1.14 BILLION (REUTERS POLL DKK 1.18 BILLION).
June 19 (Reuters) - Novadaq Technologies Inc :Novadaq enters into agreement to be acquired by stryker corporation.Novadaq technologies inc - deal for total equity value of approximately us$701 million.Novadaq technologies says stryker has agreed to acquire all of issued and outstanding shares of novadaq for us$11.75 per share in cash.Novadaq technologies says transaction will be carried out by way of court approved plan of arrangement under canada business corporations act.Novadaq technologies inc - arrangement agreement provides for payment of termination fee of $21.0 million by novadaq to stryker in certain circumstances.
June 8 (Reuters) - Cantel Medical Corp ::Cantel Medical reports financial results for the third quarter ended April 30, 2017.Q3 non-GAAP earnings per share $0.51.Q3 GAAP earnings per share $0.42.Q3 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Q3 revenue $192.1 million versus I/B/E/S view $193.8 million.Cantel Medical Corp says "we expect further restructuring costs to occur in Q4 of fiscal 2017".Cantel Medical Corp says order intake remained strong in q3, and backlog ended at record level for fourth consecutive quarter.
May 25 (Reuters) - Medtronic Plc ::Medtronic reports fourth quarter and fiscal year 2017 financial results.Q4 non-GAAP earnings per share $1.33.Q4 GAAP earnings per share $0.84.Q4 earnings per share view $1.31 -- Thomson Reuters I/B/E/S.Medtronic Plc - Q4 revenue of $7.9 billion grew 5% as reported; 5% at constant currency.Medtronic Plc - RTG worldwide Q4 revenue of $1.951 billion increased 4 percent, or 5 percent on a constant currency basis.Medtronic Plc - CVG worldwide q4 revenue of $2.848 billion increased 4 percent, or 5 percent on a constant currency basis.Medtronic Plc - in fiscal year 2018, company expects constant currency revenue growth to be in range of 4 to 5 percent.Medtronic Plc - in fiscal year 2018, company expects diluted non-GAAP EPS growth to be in range of 9 to 10 percent on a constant currency basis.Medtronic Plc - spine Q4 revenue of $676 million increased 3 percent on both a reported and constant currency basis.Medtronic Plc - reiterated its long-term expectation of mid-single digit revenue growth and double digit EPS growth, both on a constant currency basis.Medtronic Plc -in fiscal year 2018 non-GAAP EPS would be negatively affected by approximately $0.05 to $0.10, with about $0.03 to $0.05 impact in Q1.Medtronic - 2018 guidance does not include impact of previously announced divestiture of portion of patient monitoring and recovery division to Cardinal Health.Fy2018 earnings per share view $4.96, revenue view $30.87 billion -- Thomson Reuters I/B/E/S.
May 23 (Reuters) - Cerus Corp :Cerus provides U.S. business update.A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets.Fresenius Kabi has stated that it is working with its suppliers and FDA to resolve this delay.Cerus Corp says updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to prior range of $43 million to $48 million.Cerus Corp - believe shortage could "adversely" affect intercept platelet production by impacted blood centers through year end.Cerus Corp - received notification last week of a pending U.S. supply shortage of a platelet additive solution manufactured and sold by fresenius kabi.Cerus Corp - pending shortage is due to an unanticipated delay in FDA approval of a plastic component used in manufacture of pas container.
Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.